Alliance for Pandemic Preparedness

March 1, 2021

Reanalysis of the Pfizer MRNA BNT162b2 SARS-CoV-2 Vaccine Data Fails to Find Any Increased Efficacy Following the Boost Implications for Vaccination Policy and Our Understanding of the Mode of Action

Category:

Topic:

Keywords (Tags):

  • [Pre-print, not peer-reviewed] A study exploring the timing of protection conferred by the Pfizer/BioNTech vaccine indicated that the vaccine was effective beginning 11 days following the first dose, suggesting that vaccine protection precedes the full development of neutralizing antibodies. In addition, efficacy did not increase following the second dose (compared to the period between day 11 and 28).  

Saul et al. (Mar 1, 2021). Reanalysis of the Pfizer MRNA BNT162b2 SARS-CoV-2 Vaccine Data Fails to Find Any Increased Efficacy Following the Boost Implications for Vaccination Policy and Our Understanding of the Mode of Action. Pre-print downloaded Mar 1 from https://doi.org/10.1101/2021.02.23.21252315